Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02710331 · ClinicalTrials.gov registry record · Phase 1
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III
A Phase 1 study of Cannabis and Alcohol Effect, sponsored by Yale University.
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02710331: Active Phase 1 study of Cannabis and Alcohol Effect, sponsored by Yale University.
NCT02710331 is a Phase 1 study of Cannabis and Alcohol Effect that is active but no longer recruiting, run by Yale University. The registered enrollment target is 40 participants, below the 109-participant average among 24 other Cannabis trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02710331, a Phase 1 study of Cannabis and Alcohol Effect, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Active Ethanol
- DRUG Active Dronabinol
Study Locations (1)
Connecticut
- Biological Studies Unit, VA Connecticut Healthcare System - West Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-03 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What the registry record for NCT02710331 still lists
NCT02710331 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 109-participant average among 24 other Cannabis trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Cannabis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02710331 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT02710331 about?
NCT02710331 is a clinical study titled "Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III". The overarching goal of this study is to characterize the effects of ethanol and cannabinoids on simulated driving and related cognition.
What is the current status of trial NCT02710331?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-03. Estimated completion is 2025-12.
What conditions does trial NCT02710331 study?
This clinical trial studies the following conditions: Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs.
What interventions are being tested in trial NCT02710331?
The interventions under investigation include: Placebo (DRUG), Active Ethanol (DRUG), Active Dronabinol (DRUG).
Who is sponsoring clinical trial NCT02710331?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02710331 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cannabis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02710331's enrollment target sits among peer trials
40 14th of 24 higher than 7 of 24 other Cannabis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cannabis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II
RECRUITING · Phase 1
-
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I
RECRUITING · Phase 1
-
Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II
ACTIVE NOT RECRUITING · Phase 1
-
Cannabinoids, Learning, and Memory
ACTIVE NOT RECRUITING · Phase 1
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia